Literature DB >> 7152137

Inhibition of glucagon secretion by exogenous glucagon in the isolated, perfused dog pancreas.

K Kawai, R H Unger.   

Abstract

To determine if glucagon can inhibit its own secretion, exogenous glucagon was perfused in the isolated canine pancreas at concentrations ranging from 90 to 1050 pg/ml during either stimulation or suppression of endogenous glucagon secretion. When endogenous glucagon secretion was completely suppressed by the addition of 200 mg/dl of glucose to the perfusate, the concentration of glucagon in the venous effluent ranged from 80.8 to 89.9% of the level perfused; these deficits of 10-20% were attributed to uptake and/or degradation of exogenous glucagon by the pancreas. By contrast, when endogenous glucagon secretion was stimulated by perfusing with 10 mM arginine or by glucopenia of 25 mg/dl, there was a significant increase in the glucagon deficit (the efflux glucagon level during glucagon perfusion minus the sum of the pre-perfusion efflux level of endogenous glucagon and the concentration of glucagon perfused); only 60-76% of the expected glucagon concentration was present in the venous efflux. This increase in deficit is assumed to reflect suppression of endogenous glucagon. The glucagon deficit rose progressively with deficit reached the approximate level of endogenous glucagon, at which no further increase occurred, suggesting that suppression at that point was complete. To determine if the glucagon-suppressing action of glucagon was mediated by an increase in glucagon-stimulated insulin or somatostatin secretion, these hormones were measured in the various experiments. Insulin and somatostatin increased significantly when glucagon was perfused with the glucose arginine-containing solution but did not rise significantly when the glucopenic buffer was used, although suppression of endogenous glucagon was similar in each instance. It is concluded that glucagon suppresses glucagon secretion. Evidence that insulin and/or somatostatin mediate this action could not be obtained.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7152137     DOI: 10.2337/diab.31.6.512

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  The endocrine pancreas of glucagon- and somatostatin-immunized rabbits. II. Electron microscopy.

Authors:  A Jörns; D Grube
Journal:  Cell Tissue Res       Date:  1991-08       Impact factor: 5.249

2.  Binding and internalization of somatostatin, insulin, and glucagon by cultured rat islet cells.

Authors:  M Amherdt; Y C Patel; L Orci
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 3.  Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.

Authors:  L S Farhy; A L McCall
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

4.  Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.

Authors:  A Ohneda; T Kobayashi; J Nihei
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

5.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

6.  Pancreatic network control of glucagon secretion and counterregulation.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

7.  Ex-vivo isolated perfusion of the pancreas in the Syrian golden hamster.

Authors:  R H Bell; S Place; P McCullough; M B Ray; D H Rogers
Journal:  Int J Pancreatol       Date:  1986-05

8.  Lack of direct inhibition of insulin secretion by exogenous insulin in the canine pancreas.

Authors:  J Stagner; E Samols; K Polonsky; W Pugh
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes.

Authors:  Leon S Farhy; Alice Chan; Marc D Breton; Stacey M Anderson; Boris P Kovatchev; Anthony L McCall
Journal:  Front Physiol       Date:  2012-02-28       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.